The percentage of participants who discontinued the medication due to AE ranged between 20 and 29%
Leah Joseph, MD at JosephCareRX, is here to assist patients in understanding and managing insurance prior authorization for GLP-1s, ensuring smoother access to the medication
GLP 1 & GIP therapy is the latest in the new generation of weight loss medications
An exercise routine
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
Aerobic exercise did not change that ratio significantly
